Phase II study of Trastuzumab in combination with TS-1 and Cisplatin for patients with Human Epidermal Growth Factor Receptor type-2 (HER-2)-positive Advanced Gastric Cancer

Trial Profile

Phase II study of Trastuzumab in combination with TS-1 and Cisplatin for patients with Human Epidermal Growth Factor Receptor type-2 (HER-2)-positive Advanced Gastric Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Gimeracil/oteracil/tegafur (Primary) ; Cisplatin; Trastuzumab
  • Indications Gastric cancer; Oesophageal cancer
  • Focus Therapeutic Use
  • Acronyms T-SPACE
  • Most Recent Events

    • 11 Oct 2016 Results of biomarker analysis presented at the 41st European Society for Medical Oncology Congress.
    • 31 Jan 2014 According to University Hospital Medical Information Network - Japan record study status changed from recruiting to active, no longer recruiting.
    • 03 Jun 2013 Planned number of patients changed from 35 to 55 as reported by University Hospital Medical Information Network - Japan record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top